COMP <GO>
KRYS vs KYMR // EV/EBITDA & P/E VALUATION
Krystal Biotech Inc. (NASDAQ) VS. Kymera Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: KRYS 5
— KYMR 5
■ METRIC PARITY
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
valuation
53.4x
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. KYMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | KYMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | -21.40% | +37.90 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 53.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | -2.30% | +4.27 | KRYS | /fcf-yield <GO> |
| Operating Margin | 41.50% | -60.00% | +101.50 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 68.00% | -15.40 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | -16.70% | +50.60 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 61.6 | -13.40 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.95 | -0.04 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 30.4x | +9.00 | KYMR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $10.19B | -$588.0M | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | KYMR REV | KRYS GROSS % | KYMR GROSS % | KRYS FCF | KYMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $39.2M | — | 0.0% | $188.9M | -$234.3M |
| FY 2024 | $290.5M | $47.1M | — | 0.0% | $119.2M | -$207.3M |
| FY 2023 | $50.7M | $78.6M | — | — | -$91.1M | -$106.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
KYMR // BETA 0.95